Versant Capital Management
PRCT icon

Versant Capital Management’s Procept Biorobotics PRCT Stock Holding History

Versant Capital Management’s Portfolio PRCT Stock Details PRCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$37K Buy
2,032
+839
+70% +$16.7K ﹤0.01% 1620
2026
Q2 		$26.9K Buy
1,193
+1,084
+994% +$27.1K ﹤0.01% 1773
2026
Q1 		$2.73K Buy
+109
New +$3.07K ﹤0.01% 2511

Other funds holding PRCT

JP Morgan Chase
JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $106B AUM 2.29% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $71.4B AUM 33.43% 1-Year Est. Return
Fiera Capital (Canada)
Fiera Capital (Canada) Montreal, Quebec, Canada $25.3B AUM 15.9% 1-Year Est. Return
Champlain Investment Partners
Champlain Investment Partners Burlington, Vermont $2.9B AUM 23.58% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $294B AUM 47.59% 1-Year Est. Return
Rhenman & Partners Asset Management
Rhenman & Partners Asset Management Stockholm, Sweden $903M AUM 49.67% 1-Year Est. Return
Chicago Capital
Chicago Capital Chicago, Illinois $4.32B AUM 31.14% 1-Year Est. Return

Versant Capital Management's PRCT Position: Q3 2026 in Review

Versant Capital Management increased its Procept Biorobotics (PRCT) stake by 70% in Q3 2026, buying an estimated $16.7K and bringing the position to 2,032 shares worth $37K. The position accounts for ﹤0.01% of the portfolio, ranked #1620.

Versant Capital Management first reported a position in PRCT in Q1 2026 and has held it in 3 quarters since. 137 funds tracked by Wall St. Rank hold PRCT as of Q3 2026.

  • Versant Capital Management held 2,032 shares of Procept Biorobotics worth $37K as of Q3 2026.
  • Versant Capital Management bought 839 Procept Biorobotics shares in Q3 2026, an estimated $16.7K.
  • Procept Biorobotics made up ﹤0.01% of Versant Capital Management's portfolio in Q3 2026, its #1620 holding.
  • Versant Capital Management first reported a position in Procept Biorobotics in Q1 2026 and has held it in 3 quarters since.
  • 137 funds tracked by Wall St. Rank held Procept Biorobotics as of Q3 2026.

Based on Versant Capital Management's 13F filing for Q3 2026, filed 2 Oct 2026.